Physician profile
Stephanie Ham
NPI 1861001794
$2,678.23
in general payments reported to CMS, 2019-2025
30 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $604 · 2023: $515 · 2024: $748 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $576.33 | 2021-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $305.94 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $256.53 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $235.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $188.86 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $169.55 | 2022-2025 | |
| Abbvie INC. | $152.70 | 2024-2025 | |
| Seagen INC. | $146.66 | 2022-2023 | Tivdak, Tukysa |
| Astellas Pharma US INC | $97.17 | 2025 | Vyloy |
| Janssen Biotech, INC. | $74.20 | 2021-2024 | Tecvayli, Talvey, Imbruvica |
| Incyte Corporation | $46.20 | 2023-2024 | Monjuvi |
| Puma Biotechnology, INC. | $45.19 | 2021-2023 | Nerlynx |
| Amgen INC. | $32.66 | 2021-2022 | |
| Acrotech Biopharma INC. | $32.35 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $31.34 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $24.92 | 2024 | Epkinly |
| Emd Serono, INC. | $24.74 | 2025 | |
| Lilly USA, LLC | $23.43 | 2023 | Jaypirca |
| Alexion Pharmaceuticals, INC. | $22.71 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $21.23 | 2022 | |
| Aveo Pharmaceuticals, INC. | $20.14 | 2024 | |
| Sobi, INC | $19.61 | 2022 | |
| Tersera Therapeutics LLC | $18.67 | 2023 | Xermelo |
| Pfizer INC. | $17.62 | 2024 | |
| Exelixis INC. | $17.37 | 2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $16.95 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.77 | 2022 | |
| Taiho Oncology, INC. | $15.73 | 2024 | |
| G1 Therapeutics, INC. | $15.60 | 2023 | Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.